Financial Performance - The company's operating revenue for 2019 was CNY 646,903,716.16, representing a 41.12% increase compared to CNY 458,419,766.50 in 2018[22]. - The net profit attributable to shareholders for 2019 was CNY 306,889,255.38, which is a 41.92% increase from CNY 216,243,022.12 in 2018[22]. - The net cash flow from operating activities reached CNY 275,365,341.16, marking an 85.40% increase from CNY 148,522,131.12 in 2018[22]. - The total assets at the end of 2019 amounted to CNY 1,606,021,278.37, a 30.81% increase from CNY 1,227,718,370.44 at the end of 2018[22]. - The basic earnings per share for 2019 was CNY 0.7689, up 41.29% from CNY 0.5442 in 2018[22]. - The company reported a weighted average return on equity of 26.13% for 2019, an increase of 2.54% from 23.59% in 2018[22]. - The net profit excluding non-recurring gains and losses was CNY 267,205,466.84, reflecting a 40.88% increase from CNY 189,664,592.23 in 2018[22]. - The company achieved quarterly revenues of CNY 222,512,171.68 in Q3 2019, the highest among the four quarters[24]. - The company received government subsidies amounting to CNY 7,495,042.19 in 2019, compared to CNY 5,349,668.10 in 2018[28]. - The total equity attributable to shareholders at the end of 2019 was CNY 1,330,428,627.01, a 29.93% increase from CNY 1,023,966,896.23 at the end of 2018[22]. Product Development and Innovation - The company is actively developing new care products and safety monitoring systems to improve user care and reduce potential risks[5]. - The company launched the DreamVisionGP series of daily wear rigid gas permeable contact lenses, which reduces myopic defocus and irregular cornea fitting, enhancing comfort and usability[40]. - The company has developed a smart disinfection box for contact lenses, which is currently in the trial phase, aimed at enhancing user experience[89]. - The company has initiated the development of personalized contact lens care products, addressing essential daily needs for users[89]. - The company aims to expand its product and technology range through investments in various medical device companies, enhancing its market competitiveness[42]. Market Expansion and Competition - The company is facing intensified competition with 1 domestic and 7 imported brands of orthokeratology lenses approved by the National Medical Products Administration, prompting the company to enhance product innovation and marketing strategies[8]. - The company is committed to expanding its market presence through product innovation, personalized services, and potential mergers and acquisitions[8]. - The company has maintained strong relationships with hospitals and academic institutions, contributing to its leading position in technology and brand image[48]. - The company expanded its marketing network by adding over 100 new partner hospitals and retail institutions across the country in 2019[52]. - The company has established multiple new subsidiaries to expand market share, including 合肥珍视视特佳视光科技有限公司 and 天津欧普康视光学科技有限公司[125]. Risk Management and Compliance - The company acknowledges the risks associated with changes in national policies regarding medical device production and operation[5]. - The company has implemented a risk prevention system to ensure product quality and compliance with industry standards, including ISO certifications[54]. - The company faces risks from changes in national industry policies and product legal risks, particularly concerning the safety of medical devices like orthokeratology lenses[136]. - To mitigate risks from concentrated raw material suppliers, the company has established long-term contracts with Bausch & Lomb and agreements with alternative suppliers[136]. Corporate Governance and Shareholder Relations - The company guarantees the accuracy and completeness of its prospectus, assuming legal responsibility for any false statements or omissions[152]. - The company has committed to maintaining the stability of its stock price for three years post-listing[151]. - The company has committed to strictly fulfill all public commitments made during its initial public offering and will actively accept social supervision[154]. - The company has confirmed that all commitments made to minority shareholders have been fulfilled on time[157]. - The company has stated that it will accept legal responsibility for any losses caused to investors due to unfulfilled commitments[157]. Research and Development - The company’s R&D investment in 2019 amounted to ¥16,084,517.95, representing 2.49% of its operating revenue, a decrease from 2.80% in 2018[90]. - The number of R&D personnel increased to 68 in 2019, accounting for 23.53% of the total workforce, down from 34.17% in 2018[90]. - The company plans to enhance R&D investment and increase the number of R&D personnel and equipment in 2020[134]. - The company aims to shorten the R&D and technology transfer cycles for new products while ensuring compliance and high quality, thereby enhancing the competitiveness of new products[61]. Social Responsibility and Corporate Ethics - The company emphasizes social responsibility by balancing economic and social benefits, aiming for harmonious development with employees, society, and the environment[197]. - The company adheres to legal requirements for corporate governance, enhancing internal management and control systems to protect the rights of all shareholders, especially minority shareholders[197]. - The company maintains high-quality information disclosure, ensuring equal access to information for all shareholders and improving transparency and credibility through various communication channels[197]. - The company follows a "people-oriented" talent philosophy with a comprehensive compensation system and different incentive measures for various positions to foster employee loyalty and growth[198].

Financial Performance - Operating revenue for the period reached ¥222,512,171.68, reflecting a growth of 42.25% year-on-year[5] - Net profit attributable to shareholders was ¥112,738,233.74, an increase of 37.43% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥103,934,672.22, up 39.31% year-on-year[5] - Basic earnings per share for the period were ¥0.2818, a 36.93% increase from the previous year[5] - The weighted average return on equity was 9.72%, an increase of 0.76% compared to the previous year[5] - Total operating revenue for the third quarter reached ¥484,989,216.96, a significant increase of 46.8% compared to ¥330,158,223.55 in the same period last year[40] - Net profit for the third quarter was ¥223,065,212.76, up 34.7% from ¥165,612,678.64 year-over-year[41] - Basic earnings per share increased to ¥0.5759 from ¥0.4163, reflecting a growth of 38.3%[43] - Total profit for the current period was ¥135,318,800.76, a 37.83% increase from ¥98,137,348.68 in the prior period[35] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥208,851,542.64, showing a growth of 49.48%[5] - Cash flow from operating activities for the first nine months of 2019 was RMB 208,851,542.64, up 49.48% from RMB 139,722,707.86 in the same period of 2018[17] - Cash and cash equivalents increased by 48.16% to RMB 264,146,854.42 due to growth in operating income and increased sales collections[13] - The total assets reached CNY 1,510,736,298.53, up from CNY 1,227,718,370.44, marking a growth of around 22.98%[27] - Cash and cash equivalents at the end of the period totaled ¥264,146,854.42, up from ¥198,266,491.90 at the end of Q3 2018, representing a 33% increase[48] - The total current assets as of September 30, 2019, amounted to CNY 1,167,780,819.99, an increase from CNY 997,280,816.81 as of December 31, 2018, reflecting a growth of approximately 17.06%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,019[8] - The largest shareholder, Tao Yuequn, holds 37.22% of the shares, totaling 150,328,904 shares[8] Operating Costs and Expenses - The company's total operating costs for the first nine months of 2019 were RMB 248,102,686.01, a 58.74% increase from RMB 156,293,424.75 in the same period of 2018[15] - Total operating costs amounted to ¥97,625,751.25, up 47.88% from ¥66,079,589.19 in the prior period[34] - Research and development expenses were ¥3,851,928.21, a 28.06% increase from ¥3,007,701.96 in the prior period[34] - Sales expenses increased to ¥34,469,150.64, up 69.54% from ¥20,332,576.90 in the previous period[34] Investments and Financial Position - The company has invested CNY 300,000,000.00 in a principal-protected financial product with a yield of 4.40%[22] - The company reported a total of CNY 49,900,881.09 in long-term equity investments, significantly up from CNY 1,221,732.51[27] - The company’s goodwill increased by 50.29% to RMB 67,724,505.25, primarily due to the acquisition of subsidiaries under non-common control[14] - The company reported a capital reserve of CNY 378,557,270.05 and a surplus reserve of CNY 63,260,495.60[59] Tax and Compliance - The company reported a tax expense of ¥21,211,145.80, which is 38.06% higher than ¥15,343,480.95 from the previous period[35] - The company has not reported any violations regarding external guarantees during the reporting period[24] - The company has not disclosed any significant changes in its cash dividend policy during the reporting period[23] - The company has not undergone an audit for the third-quarter report, indicating that the figures are unaudited[60]

Financial Performance - Total revenue for the reporting period reached ¥262,477,045.28, representing a 51.08% increase compared to ¥173,735,847.90 in the same period last year[14]. - Net profit attributable to shareholders was ¥116,617,406.11, up 39.75% from ¥83,449,373.44 year-on-year[14]. - The net profit after deducting non-recurring gains and losses was ¥97,867,303.51, reflecting a 39.42% increase from ¥70,197,004.26 in the previous year[14]. - The net cash flow from operating activities was ¥90,487,521.34, an increase of 27.39% compared to ¥71,030,245.61 in the same period last year[14]. - Basic earnings per share were ¥0.2916, up 39.26% from ¥0.2094 in the same period last year[14]. - Total assets at the end of the reporting period were ¥1,348,337,166.50, a 9.82% increase from ¥1,227,718,370.44 at the end of the previous year[14]. - Net assets attributable to shareholders increased by 9.34% to ¥1,119,643,968.22 from ¥1,023,966,896.23 at the end of the previous year[14]. - The company achieved operating revenue of ¥262,477,045.28, a year-on-year increase of 51.08%[23]. - The company reported non-recurring gains totaling ¥18,750,102.60 for the reporting period[18]. - The company’s long-term equity investments increased by 2,049.45%, reaching ¥26,260,500, primarily due to new investments[25]. - Cash and cash equivalents rose by 48.36% to ¥264,507,400, driven by increased operating revenue and sales collections[25]. Market Position and Strategy - The company focuses on non-surgical vision correction and is gradually evolving into a comprehensive optical product R&D and manufacturing enterprise[20]. - The core product, "DreamVision" series orthokeratology lenses, is designed to temporarily reshape the cornea to reduce myopia during sleep[21]. - The company launched the DreamVisionGP daily wear contact lens, which has received positive feedback for comfort and usability[27]. - The company is the first in mainland China to obtain registration certificates for both orthokeratology lenses and rigid gas permeable lenses[24]. - The company’s market position is strengthened by its leadership in the orthokeratology lens segment, supported by extensive clinical data and experience[29]. - The company plans to enhance product competitiveness through regular innovation, personalized services, and marketing support to address intensified competition in the market[78]. - The company has established long-term supply contracts with its primary supplier, Bausch + Lomb, to ensure stability in supply and pricing[77]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2020[153]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration, with an estimated cost of 500 million RMB[153]. Research and Development - The company’s R&D efforts led to the approval of new product registrations and innovations in contact lens technology[27]. - Research and development expenses increased by 37.95% to approximately ¥6.83 million, reflecting the company's commitment to innovation[47]. - The company plans to enhance its research and development capabilities to innovate new technologies and products[126]. - The company is focused on developing new technologies and products in the medical optical field to maintain competitive advantage[136]. - Research and development expenses increased by 30% to 200 million RMB, reflecting the company's commitment to innovation and technology advancement[153]. Risk Management - The company faces legal risks associated with its medical optical devices, particularly those that are implanted or in long-term contact with the body, which could lead to lawsuits affecting business and financial status[4]. - The company acknowledges the risk of technological advancements by competitors that could impact its product competitiveness and profitability[6]. - The company emphasizes the importance of internal quality control systems to prevent product quality issues that could harm users[4]. - The company has built a comprehensive risk prevention system focused on "safety first," which includes strict regulations on applicable populations and symptoms[36]. - The company has implemented measures to mitigate risks associated with changes in national industry policies and product safety[76]. Corporate Governance - The company has stated that all board members attended the meeting to review the report, ensuring accountability for the report's accuracy[4]. - The company’s financial statements were approved by the board on August 27, 2019, indicating a commitment to transparency and governance[137]. - The semi-annual financial report was not audited[103]. - The company has not disclosed any significant related party transactions during the reporting period[82]. - The company has not faced any major litigation or arbitration matters during the reporting period[81]. Shareholder Information - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[6]. - The largest shareholder, Tao Yuequn, holds 37.22% of the shares, totaling 150,328,904 shares, with 51,256,800 shares pledged[95]. - The total number of shareholders at the end of the reporting period was 13,883[95]. - The company distributed 1.4 RMB in cash for every 10 shares and increased the share capital by 8 shares for every 10 shares held[93]. - The diluted earnings per share for the year 2018, after the share increase, was calculated to be 0.5354 RMB[93]. Financial Management - The company has implemented cash management strategies to enhance the efficiency of idle funds, with a balance of 2 million RMB remaining unrecovered as of June 30, 2019[64]. - The company has not engaged in derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[69]. - The company emphasizes strict supplier selection and procurement cost control, resulting in lower procurement costs than planned[64]. - The company has adjusted its investment scope for idle raised funds to include a wider range of financial products, enhancing flexibility in fund management[64]. Subsidiaries and Expansion - The company added 24 subsidiaries during the reporting period, expanding its medical and optical technology services[37]. - The company established approximately 100 vision service terminals across various provinces, enhancing its market presence[37]. - The company has a total of 40 subsidiaries, with ownership stakes ranging from 51% to 100% in various entities[137]. - The company has closed two subsidiaries in 2019, indicating a strategic decision to streamline operations[141]. Inventory and Assets - The company’s inventory increased to RMB 53,462,466.49, representing 3.97% of total assets, compared to 3.43% in the previous year[53]. - The company holds inventory classified as finished goods, work in progress, and raw materials, essential for its operations in the medical device industry[183]. - The company’s total liabilities increased to ¥153,202,674.08 from ¥145,281,842.59, reflecting a rise of approximately 5.3%[107]. - The total non-current assets amounted to RMB 284,000,000.00, up from RMB 246,000,000.00 at the end of 2018, reflecting an increase of approximately 15.4%[105]. Financial Instruments and Accounting - Financial instruments are recognized when the company becomes a party to the contract, and financial assets or liabilities are confirmed accordingly[162]. - The company uses the effective interest method for subsequent measurement of financial assets classified at amortized cost, with gains or losses recognized in profit or loss[165]. - The company maintains a clear policy on the offsetting of financial assets and liabilities, ensuring compliance with accounting standards[172]. - The company emphasizes the importance of observable inputs in fair value measurement, using unobservable inputs only when necessary[173].

Financial Performance - Total revenue for Q1 2019 reached ¥121,047,109.63, representing a 56.74% increase compared to ¥77,228,614.27 in the same period last year[4] - Net profit attributable to shareholders was ¥50,503,031.72, up 41.79% from ¥35,618,763.22 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥43,177,140.64, reflecting a 41.26% increase from ¥30,564,822.98 in the previous year[4] - Basic and diluted earnings per share were both ¥0.2292, marking a 41.74% increase from ¥0.1617 in the previous year[4] - The total profit for the current period was ¥56,748,202.83, compared to ¥41,789,097.84 in the previous period, reflecting an increase of approximately 35.8%[35] - The company’s total comprehensive income for the current period was ¥51,863,970.16, compared to ¥36,066,503.94 in the previous period, indicating a growth of around 43.5%[39] Cash Flow - Operating cash flow for the period was ¥44,070,819.54, an increase of 17.15% compared to ¥37,617,862.44 in the same quarter last year[4] - The company's operating cash inflow for the current period was CNY 141,764,313.48, an increase of 38.5% compared to CNY 102,335,048.60 in the previous period[42] - The net cash flow from operating activities was CNY 44,070,819.54, up from CNY 37,617,862.44, reflecting a growth of 12.2%[42] - The net cash flow from investment activities was CNY 24,735,285.33, a significant recovery from a negative CNY 44,015,251.05 in the previous period[42] - The company's cash and cash equivalents at the end of the period totaled CNY 252,243,389.49, up from CNY 159,795,811.56, marking a growth of 57.7%[43] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,316,161,824.30, a 7.20% increase from ¥1,227,718,370.44 at the end of the previous year[4] - The total current assets amounted to CNY 1,059,375,371.51, an increase from CNY 997,280,816.81 as of December 31, 2018, reflecting a growth of approximately 6.9%[26] - The total liabilities increased to CNY 166,047,644.02 from CNY 145,281,842.59, reflecting a rise of about 14.26% year-over-year[28] - The owner's equity totaled CNY 1,150,114,180.28, up from CNY 1,082,436,527.85, indicating an increase of approximately 6.27%[29] - The total assets as of March 31, 2019, were CNY 1,316,161,824.30, compared to CNY 1,227,718,370.44 at the end of 2018, representing an increase of approximately 7.2%[27] Investments and Expenditures - The company’s long-term equity investments rose by 216.22% to 3,863,325.25 yuan due to new investments in joint ventures[13] - The project for producing 400,000 orthokeratology lenses and related products has achieved 59.84% of its planned investment[22] - The engineering technology and training center project has reached 36.47% of its planned investment[22] - The marketing service network construction project has achieved 45.99% of its planned investment[22] - The company has invested a total of 35,946 million CNY in fundraising, with 1,803.93 million CNY allocated in the current quarter[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,519[7] - The largest shareholder, Tao Yuequn, holds 37.22% of the shares, amounting to 83,516,058 shares[8] Operational Highlights - The company reported government subsidies amounting to ¥1,093,091.85 during the reporting period[6] - The company has implemented the ISO13485 quality management system to enhance product safety and quality control[19] - The company has established a long-term supply contract with Bausch & Lomb to ensure stable supply and favorable pricing for raw materials[19] - The company is facing increased competition with 7 imported brands and 1 newly approved domestic brand in the orthokeratology lens market[19] - The company is focusing on product innovation, personalized services, and marketing support to enhance competitiveness[19] Research and Development - Research and development expenses amounted to ¥2,710,234.27, up from ¥2,338,011.17, which is an increase of about 16.0%[34] - The company aims to enhance product development through independent and collaborative research, as well as investments in subsidiaries[17] - The company is developing new products such as sterile rinsing solution and remote corneal monitoring systems to improve user safety[19]

Financial Performance - The company's revenue for 2018 was CNY 458,419,766.50, representing a 47.10% increase compared to CNY 311,629,075.06 in 2017[14]. - The net profit attributable to shareholders for 2018 was CNY 216,243,022.12, up 43.34% from CNY 150,858,703.52 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was CNY 189,664,592.23, reflecting a 40.53% increase from CNY 134,965,417.39 in 2017[14]. - The total assets at the end of 2018 amounted to CNY 1,227,718,370.44, a 33.08% increase from CNY 922,568,699.14 at the end of 2017[14]. - The net assets attributable to shareholders reached CNY 1,023,966,896.23, which is a 27.20% increase compared to CNY 804,979,107.56 in 2017[14]. - The basic earnings per share for 2018 was CNY 0.9795, representing a 41.77% increase from CNY 0.6909 in 2017[14]. - The diluted earnings per share was CNY 0.9764, up 41.32% from CNY 0.6909 in the previous year[14]. - The weighted average return on equity for 2018 was 23.59%, an increase of 2.19% from 21.40% in 2017[14]. - The net cash flow from operating activities for 2018 was CNY 148,522,131.12, a slight increase of 2.63% from CNY 144,709,478.21 in 2017[14]. Product and Market Development - The company operates in the medical device sector, specifically in the category of Class III medical devices, which poses legal risks related to product quality and user safety[3]. - The core product, the "DreamVision" orthokeratology lens, is designed to temporarily reduce myopia by reshaping the cornea, with increasing demand driving sales growth[19]. - The company launched the DreamVision orthokeratology lens in 2018, which allows for a maximum myopia reduction of 600 degrees, surpassing the typical market limit of 500 degrees[25]. - The company is the first in mainland China to receive regulatory approval for orthokeratology lenses, establishing a strong market position[22]. - The company’s products include rigid gas permeable contact lenses and orthokeratology lenses, which are designed to correct vision and improve user comfort[6]. - The company is committed to improving product quality and user experience through advanced technologies such as plasma treatment for lens surfaces[6]. - The company has strengthened sales channel development and technical training, leading to rapid growth in previously weaker regions[20]. - The company has established a comprehensive marketing network, increasing its cooperative hospitals and retail institutions by over 100 in 2018, with its products now available in approximately 800 hospitals[30]. Research and Development - The company has a strong talent pool with a diverse professional background, enhancing its research and development capabilities[29]. - The total R&D investment amounted to CNY 12,837,727.98 in 2018, accounting for 2.80% of operating revenue[64]. - The company has 68 R&D personnel, which constitutes 34.17% of the total workforce[64]. - The company is in the application stage for the "Smart Little Dream" system, enhancing product lines and market competitiveness[62]. - The new "Dreamvision" fitting and design system is in the promotion stage, representing a new technological advancement in the field[63]. - The company has several new products under development, including a cleaning solution and a tear secretion test strip, with registration applications currently under review[36]. Supply Chain and Procurement - The company acknowledges the risks associated with concentrated supplier relationships, which could impact operations if disruptions occur[4]. - The company’s main raw material supplier is USCH & LOMB INCORPORATED, with procurement amounts increasing annually alongside business growth[4]. - The company has established a long-term supply contract with Bausch & Lomb for raw materials, ensuring supply stability[88]. - The total procurement amount from the top five suppliers was ¥88,735,079.10, representing 77.34% of the annual total procurement[58]. - The company’s top supplier accounted for 68.11% of the total procurement amount, indicating a high dependency on key suppliers[59]. Risk Management - The company faces technology risks due to rapid industry changes and potential competition from advanced technologies or imitators[4]. - The company emphasizes the importance of internal quality control to prevent product quality issues that could harm users[3]. - The company has developed a risk prevention system focused on "safety first," achieving ISO9001 and ISO13485 certifications for quality management[31]. - The company is facing risks from intensified competition, with 7 other imported brands approved for the orthokeratology lens market[88]. - The company will implement measures such as product innovation and brand promotion to enhance competitiveness in response to market challenges[88]. Shareholder and Governance - The company reported a commitment to repurchase shares if the stock price falls below the latest audited net asset value per share for 20 consecutive trading days[102]. - The company has promised to stabilize its stock price within 36 months post-IPO, including share buybacks if necessary[102]. - The controlling shareholder has committed to not transferring or entrusting the management of shares held prior to the public offering for a lock-up period of 36 months[98]. - The company has ensured that its prospectus does not contain misleading statements or significant omissions, taking legal responsibility for its accuracy[104]. - The company has established a comprehensive internal management and control system to enhance corporate governance and protect shareholder rights[140]. - The company has committed to improving information disclosure quality to ensure equal access to information for all shareholders[140]. Employee and Management - The total remuneration for directors, supervisors, and senior management in 2018 amounted to CNY 2.5872 million[168]. - The company employed a total of 898 staff, with 514 in technical roles, 123 in sales, and 86 in production[172]. - The company has implemented a comprehensive remuneration system based on performance assessment and competitive industry standards[174]. - The company provided training opportunities for different employee levels, focusing on new employee orientation and management skills[175]. - The board of directors consists of 9 members, with 5 being current employees who do not receive additional director remuneration[168]. Future Outlook - The company expects a revenue growth of 10% for the next fiscal year, projecting a target revenue of 1.32 billion yuan[137]. - New product launches are anticipated to contribute an additional 200 million yuan in revenue in the upcoming year[138]. - The company plans to acquire a local competitor, which is expected to enhance its market position and add 100 million yuan in annual revenue[137]. - The company plans to introduce new products targeting high myopia and enhance its product line in 2019[85]. - The company will continue to enhance R&D investment and expand its brand influence through academic promotion and technical training in 2019[87].

Financial Performance - Revenue for the reporting period reached CNY 156,422,375.65, representing a 52.13% increase year-on-year[8] - Net profit attributable to shareholders was CNY 82,033,909.95, up 50.96% from the same period last year[8] - Basic earnings per share rose by 47.01% to CNY 0.3740[8] - The company reported a net profit excluding non-recurring items of CNY 74,606,614.00, a 52.56% increase year-on-year[8] - The company’s total comprehensive income for the current period was ¥165,612,678.64, compared to ¥112,810,013.55 in the previous period, representing an increase of about 46.8%[56] - Basic and diluted earnings per share increased to ¥0.7499 from ¥0.5267, reflecting a growth of approximately 42.3%[56] - Net profit for the current period was ¥78,187,238.43, compared to ¥50,946,034.39 in the previous period, marking an increase of about 53.2%[51] - The net profit for the third quarter of 2018 was CNY 175,307,930.82, an increase of 51.7% compared to CNY 115,645,472.96 in the same period last year[59] Assets and Liabilities - Total assets increased by 28.10% to CNY 1,181,782,568.19 compared to the end of the previous year[8] - The total current assets increased to CNY 973,071,413.25 from CNY 783,167,655.03, representing a growth of approximately 24.3%[38] - Total liabilities increased to CNY 165,625,448.85 from CNY 110,230,529.45, which is an increase of approximately 50.3%[40] - The total equity attributable to shareholders rose to CNY 957,252,866.64 from CNY 804,979,107.56, showing an increase of about 18.9%[40] - The company's total assets increased to ¥1,070,937,135.05 from ¥872,080,555.12, marking a growth of about 23%[43] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 139,722,707.86, an increase of 26.30%[8] - Cash flow from operating activities generated a net amount of CNY 139,722,707.86, compared to CNY 110,625,689.29 in the previous year, marking a 26.3% increase[60] - The cash flow from investment activities resulted in a net outflow of CNY -95,683,596.24, an improvement from CNY -574,132,335.39 in the same period last year[62] - The company reported a cash and cash equivalents balance of CNY 198,266,491.90 at the end of the period, up from CNY 105,539,684.49 year-over-year[63] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,086[13] - The largest shareholder, Tao Yuequn, holds 37.32% of the shares, with 83,516,058 shares pledged[13] Inventory and Receivables - Accounts receivable increased by 95.97% to RMB 73,639,888.32, primarily due to growth in operating income and the addition of new subsidiaries[19] - Inventory rose by 160.70% to RMB 49,863,794.76, driven by business expansion and new subsidiary acquisitions[19] - The company reported a significant increase in prepayments to CNY 15,147,709.04 from CNY 3,675,978.37, which is an increase of approximately 312.5%[38] Expenses and Costs - The company experienced a 222.37% increase in management expenses to RMB 27,150,150.39, attributed to stock incentive expenses and the addition of new subsidiaries[21] - Total operating costs rose to ¥26,043,956.96 from ¥17,121,994.79, indicating an increase of about 52.0%[50] Research and Development - Research and development expenses for the quarter were ¥3,007,701.96, compared to ¥2,491,068.90 in the previous period, showing an increase of about 20.7%[46] - Research and development expenses increased to ¥3,007,701.96 from ¥2,491,068.90, reflecting a growth of approximately 20.7%[50] Financial Management - The company’s financial management strategy includes utilizing idle funds for investment in financial products to optimize returns[27] - The company allocated a total of 30 million CNY in financial products with an annual net yield of 4.90% and 25 million CNY with a yield of 5.10%[27] Future Plans - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[51] - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth[59]

Financial Performance - Total revenue for the first half of 2018 reached ¥173,735,847.90, representing a 45.32% increase compared to ¥119,556,069.84 in the same period last year[23]. - Net profit attributable to shareholders was ¥83,449,373.44, up 42.80% from ¥58,438,158.98 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥70,197,004.26, reflecting a 28.56% increase from ¥54,602,182.29 in the previous year[23]. - The company's total assets increased by 14.77% to ¥1,058,790,081.38 from ¥922,568,699.14 at the end of the previous year[24]. - The net assets attributable to shareholders rose by 8.55% to ¥873,785,660.74 from ¥804,979,107.56 at the end of the previous year[24]. - Basic earnings per share increased by 36.16% to ¥0.3769 from ¥0.2768 in the same period last year[23]. - The company reported a net profit margin of 18% for the first half of 2018, reflecting a stable financial performance[123]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2018, representing a year-on-year growth of 25%[125]. Operational Highlights - The company reported stable operating performance for the first half of 2018, with no significant adverse changes in key operational metrics such as procurement scale, production, and sales prices[6]. - The company achieved operating revenue of ¥173,735,847.90, representing a year-on-year growth of 45.32%[36]. - The core product, orthokeratology lenses, continues to see rising demand, supported by personalized design and high correction levels[36]. - The company expanded its production capacity and launched a new product, DreamVision, enhancing the smart and automated features of its lenses[36]. - The company has established a comprehensive marketing network, with its products entering over 700 hospitals and achieving more than 600,000 fittings[49]. - The company has invested in regional optical service terminals in cities such as Fuzhou, Jinan, and Zhanjiang, establishing 21 optical service terminals[52]. - The company has conducted 81 basic training sessions and 42 intermediate training sessions, training over 10,000 participants to enhance service quality[46]. Research and Development - The company is focused on non-surgical vision correction and plans to enhance investment in technology and product development in the optical field[33]. - R&D expenses amounted to ¥4,947,537.98, reflecting a growth of 34.99% compared to the previous year[56]. - The company has received 2 utility model patents and 4 software copyrights in the first half of 2018, indicating ongoing innovation and development[43]. - The company’s R&D capabilities have been strengthened by hiring new employees and providing project subsidies to young R&D staff[49]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving product efficiency and user experience[125]. Market and Competitive Position - The company is the only manufacturer in mainland China with a registered product certificate for orthokeratology lenses, maintaining a leading position in the industry[38]. - The national focus on myopia prevention has led to the inclusion of orthokeratology lenses in the "Myopia Prevention Guidelines," highlighting their effectiveness[37]. - The company plans to expand its product line in lens care products, launching new items to establish its own brand in this segment[39]. - The company plans to expand its market presence by entering three new regions by the end of 2018, aiming for a 15% increase in market share[123]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2019[125]. Risks and Challenges - The company operates in the III class medical device sector, which poses legal risks related to product quality and user health impacts[4]. - The company faces technology risks due to rapid industry changes and potential competition from advanced technologies or imitation products[5]. - The company acknowledges the potential impact of environmental and individual factors on product performance and user safety[4]. - The company is aware of the challenges posed by talent competition in the specialized technology sector, which could affect operational capabilities[5]. - The company is facing risks from changes in national industry policies and product safety, particularly concerning its main product, rigid gas permeable contact lenses[111]. Shareholder Commitments and Governance - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves for the reporting period[7]. - The company has a commitment from its controlling shareholder, Tao Yuequn, to not transfer shares for a period of 36 months from January 17, 2017[119]. - The company has received commitments from major shareholders to adhere to share transfer restrictions for twelve months post-listing[121]. - The company emphasizes the importance of maintaining share price stability through these commitments from shareholders[120]. - The management team emphasized a commitment to maintaining high standards of corporate governance and transparency in all operations[126]. Financial Management and Investments - The total amount of investment during the reporting period was ¥28,699,339.71, a decrease of 48.18% compared to ¥55,385,293.27 in the same period last year[80]. - The company has committed to invest a total of 35,946 million in various projects, with 2,869.9 million already invested as of the report date[91]. - The company has utilized 11,600 million of idle raised funds for bank financial products, with 2,100 million still outstanding[96]. - The company reported a total of ¥25,924.96 million in unutilized raised funds as of June 30, 2018, including ¥7,324.96 million in the special account and ¥18,600.00 million in financial products[88]. - The company has not encountered any significant issues regarding the use and disclosure of raised funds[92].

Financial Performance - Total revenue for Q1 2018 reached ¥77,228,614.27, representing a 33.25% increase compared to ¥57,955,571.76 in the same period last year[6] - Net profit attributable to shareholders was ¥35,618,763.22, up 32.08% from ¥26,968,295.30 year-over-year[6] - Basic earnings per share rose to ¥0.29, a 20.83% increase from ¥0.24 in the same period last year[6] - Operating profit reached RMB 41,784,377.05, up 28.84% compared to the same period last year[27] - Net profit for the period was RMB 35,374,139.61, a 33.20% increase from RMB 26,556,780.50 year-on-year[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 30,564,822.98, an increase of 20.03% year-on-year[27] - The company reported a gross profit margin of approximately 47.5% for the current period, compared to 52.0% in the previous period[52] - The total profit for the current period was RMB 41,789,097.84, up from RMB 32,430,395.57 in the previous period, reflecting a growth of 28.5%[52] Cash Flow - The net cash flow from operating activities increased by 38.05%, amounting to ¥37,617,862.44 compared to ¥27,249,212.17 in the previous year[6] - Cash flow from operating activities totaled RMB 102,335,048.60, compared to RMB 74,815,907.66 in the previous period, indicating a strong cash generation capability[59] - The net cash flow from operating activities for Q1 2018 was CNY 37,617,862.44, an increase of 38.2% compared to CNY 27,249,212.17 in Q1 2017[60] - Cash inflow from investment activities totaled CNY 513,521,364.04, significantly higher than CNY 180,664,762.30 in the previous year, marking an increase of 184.5%[60] - The cash inflow from operating activities was CNY 66,201,428.94, up from CNY 58,112,430.34 in the previous year, representing an increase of 13.5%[62] - The cash outflow for investment activities was CNY 557,536,615.09, compared to CNY 469,207,477.98 in Q1 2017, reflecting an increase of 18.8%[62] Assets and Liabilities - Total assets at the end of the reporting period were ¥994,789,519.96, reflecting a 7.83% increase from ¥922,568,699.14 at the end of the previous year[6] - Total liabilities amounted to RMB 122.55 million, compared to RMB 110.23 million, reflecting a growth of 11.5%[47] - Owner's equity reached RMB 872.24 million, up from RMB 812.34 million, marking a growth of 7.4%[47] - Current assets totaled RMB 823.50 million, an increase of 5.1% from RMB 783.17 million in the previous period[45] - The total non-current assets increased to RMB 171.28 million, up from RMB 139.40 million, reflecting a growth of 22.8%[45] Shareholder Information - The number of common shareholders at the end of the reporting period was 6,781[15] - The top shareholder, Tao Yuequn, holds 37.32% of the shares, with 46,397,810 shares pledged[15] Risks and Challenges - The company faces risks related to product quality, supplier concentration, and technological advancements in its industry[11][12] - The company has identified risks related to changes in national industry policies and product legal risks that may impact operations[32] Strategic Initiatives - The company plans to enhance R&D investment and accelerate the progress of ongoing projects, aiming to strengthen market competitiveness[28] - The company is actively seeking suitable acquisition targets to integrate upstream and downstream resources in the industry chain[28] - The company plans to enhance product safety by launching self-developed sterile rinsing solution and remote corneal monitoring system[32] - The company is focusing on enhancing customer satisfaction through new product development and improved fitting technology[31] - The company plans to expand its marketing service network from five provinces to nationwide coverage, enhancing its market presence[37] Operational Changes - The company has changed its fundraising project implementation method to include joint ventures and acquisitions, in addition to wholly-owned new constructions[37] - The company did not engage in any repurchase transactions during the reporting period[17] - The company has no violations regarding external guarantees during the reporting period[38]

Financial Performance - The company's operating revenue for 2017 was ¥311,629,075.06, representing a 32.60% increase compared to ¥235,018,663.61 in 2016[16]. - The net profit attributable to shareholders for 2017 was ¥150,858,703.52, up 32.29% from ¥114,037,965.97 in 2016[16]. - The cash flow from operating activities for 2017 was ¥144,709,478.21, reflecting a 33.00% increase from ¥108,802,312.11 in 2016[16]. - The basic earnings per share for 2017 was ¥1.26, a slight increase of 1.61% from ¥1.24 in 2016[17]. - Total assets at the end of 2017 reached ¥922,568,699.14, a significant increase of 158.06% from ¥357,501,494.75 at the end of 2016[17]. - The net assets attributable to shareholders at the end of 2017 were ¥804,979,107.56, up 158.43% from ¥311,489,031.46 at the end of 2016[17]. - The company reported a diluted earnings per share of ¥1.26 for 2017, consistent with the basic earnings per share[17]. - The company experienced a 29.75% increase in net profit after deducting non-recurring gains and losses, totaling ¥134,965,417.39 in 2017[16]. - The company received government subsidies amounting to ¥3,943,147.70 in 2017, compared to ¥4,515,570.12 in 2016[20]. - The total non-recurring gains for 2017 amounted to ¥15,893,286.13, an increase from ¥10,016,136.69 in 2016[20]. Dividend Distribution - The company plans to distribute a cash dividend of 2.10 RMB per 10 shares to all shareholders, based on a total of 124,313,920 shares[7]. - The company's net profit for 2017 was 156,135,079.66 yuan, with a total distributable profit of 196,653,892.11 yuan after accounting for reserves and previous distributions[104]. - In 2017, the company distributed a cash dividend of 2.1 CNY per 10 shares, totaling 26,105,923.20 CNY, which represents 17.30% of the net profit attributable to ordinary shareholders[108]. - The cash dividend for 2016 was 78,778,000.00 CNY, accounting for 69.08% of the net profit attributable to ordinary shareholders[108]. - The total cash dividend paid in 2017 was significantly lower than the previous year's dividend, indicating a potential decrease in profitability[108]. Market Position and Product Development - The company operates in the medical device sector, specifically in the category of Class III medical devices, which includes long-term contact lenses[5]. - The company’s main product, the "DreamDaiwei" orthokeratology lens, is designed to correct myopia and is personalized based on the user's corneal geometry[26]. - The company launched the DreamVision orthokeratology lens in 2017, showcasing its R&D capabilities and innovation in the field[31]. - The company’s market position is strengthened by the increasing prevalence of myopia in China, with over 600 million affected individuals[26]. - The company plans to enhance its product offerings by launching upgraded orthokeratology lenses and has introduced a new high-end product line under the brand DreamVision[94]. - The company aims to introduce three new products in 2018, which are anticipated to contribute an additional 200 million RMB in revenue[114]. Research and Development - Research and development expenses amounted to CNY 10,396,453.02, reflecting a 32.5% increase compared to the previous year[41]. - The number of R&D personnel increased to 54 in 2017, representing 34.39% of the total workforce, up from 32.37% in 2016[67]. - The company has allocated a budget of 556.3 million for research and development in 2017, which is a 10% increase from the previous year[179]. - The company is focusing on the development of new technologies and products through collaboration and technology transfer[95]. Operational Efficiency and Risks - The company emphasizes the importance of maintaining a robust internal quality control system to mitigate product-related risks[5]. - The company faces risks related to product quality and potential legal liabilities due to the nature of its medical devices[5]. - The company is aware of the risks associated with talent retention and potential technology leaks in a competitive market[6]. - The company has a stable operating model and has not experienced significant fluctuations in procurement costs or sales prices[6]. - The company is facing risks from changes in national policies regarding medical devices and increased competition from 7 other registered brands in the market[99]. Corporate Governance and Compliance - The company has committed to adhering to industry regulations and maintaining transparency in its financial reporting[4]. - The company has established a comprehensive salary system based on performance evaluation and competitive principles[187]. - The company has implemented a robust internal control system to manage risks and ensure the normal conduct of business activities[195]. - The company respects and protects the legitimate rights and interests of stakeholders, promoting balanced development among shareholders, employees, and society[195]. - The company guarantees that the prospectus does not contain false records or misleading statements, and will bear legal responsibility for its accuracy[117]. Strategic Initiatives and Future Outlook - The company provided a positive outlook for 2018, projecting a revenue growth of 20% based on new product launches and market expansion strategies[114]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[112]. - A strategic acquisition of a local competitor is expected to enhance the company's product offerings and increase market penetration by 15%[113]. - The management emphasized a commitment to maintaining a gross margin of at least 40% through cost control measures and operational efficiencies[115]. Employee Engagement and Training - The company has implemented a comprehensive compensation system to enhance employee engagement and retention[152]. - The company provided training opportunities for employees, focusing on new employee training and management skills development[188]. - The company conducted training for over 1,000 participants in corneal molding technology, enhancing its product marketing efforts[43]. Financial Management and Investments - The company reported a significant increase in interest income, leading to a financial expense of -1,328,260.74 CNY, a decrease of 1,362.69% compared to the previous year[63]. - The company has a total of 120 million CNY in another wealth management product with an expected return of 4.50%[146]. - The company plans to continue utilizing wealth management products for idle funds, indicating ongoing investment strategies[145]. - The financial products include bank deposits, bond repos, and money market instruments, reflecting a diversified investment approach[145].

Financial Performance - Total assets reached ¥847,694,627.47, an increase of 137.12% compared to the previous year[7] - Net assets attributable to shareholders increased to ¥763,319,061.75, up 145.05% year-over-year[7] - Operating revenue for the quarter was ¥102,819,723.78, representing a growth of 41.63% compared to the same period last year[7] - Net profit attributable to shareholders was ¥54,342,107.26, a 39.09% increase year-over-year[7] - Net profit after deducting non-recurring gains and losses was ¥48,902,695.59, up 30.62% from the previous year[7] - Basic earnings per share for the quarter was ¥0.440, a slight increase of 2.33%[7] - The weighted average return on equity was 7.39%, down 39.48% compared to the same period last year[7] Cash Flow - Cash flow from operating activities for the year-to-date was ¥110,625,689.29, an increase of 35.42%[7] - The net cash flow from operating activities increased by 35.42% to CNY 116,025,689.29, up from CNY 81,691,652.74, due to increased sales and cash collections[18] - The ending balance of cash and cash equivalents was ¥105,539,684.49, down from ¥229,560,472.51 at the beginning of the period[58] - The total cash inflow from operating activities was ¥220,289,363.40, compared to ¥158,995,364.22 in the previous year, reflecting an increase of approximately 38.4%[59] - The cash outflow for purchasing goods and services was ¥63,742,703.87, up from ¥45,159,560.29 in the previous year, indicating a rise of about 41.1%[59] Investments and Assets - The company has invested CNY 460 million in structured deposits with a net annual yield of 3.99% and 4.5% from various banks, with several products still not matured[25][27] - The company’s investment income rose by 53.52% to CNY 7,482,486.63, due to increased returns from financial product investments[18] - Inventory increased by 90.27% to CNY 24,767,210.14, compared to CNY 13,017,079.19, driven by expanded sales and increased raw material stock[17] - The company reported a 248.94% increase in prepayments, totaling CNY 10,176,158.31, attributed to advance rental and equipment procurement payments[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,164[12] - The company completed a public offering, resulting in a 140.00% increase in paid-in capital to CNY 122,400,000.00 from CNY 51,000,000.00[17] - The company is in the process of completing the registration for the restricted stock grant as authorized by the shareholders[22] Compliance and Governance - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[28] - There were no violations regarding external guarantees during the reporting period[29] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[30] Operational Highlights - The marketing service network construction project has been expanded from five provinces to nationwide, with the implementation methods now including wholly-owned new construction, joint ventures, and acquisitions[23] - The original investment amount for the marketing service network project was CNY 156.2 million, which remains unchanged after the expansion[23] - The company announced that its associate, Guangzhou Weishi Bo Biotechnology Co., Ltd., received approval for its "foldable artificial vitreous body balloon" product, which can now be used clinically[19] - The company initiated a restricted stock incentive plan in August 2017, aimed at motivating and retaining key employees[19] - The company approved the 2017 Restricted Stock Incentive Plan and related matters during the second extraordinary general meeting on September 7, 2017[22] Financial Statements - The company’s financial statements are prepared in accordance with the relevant accounting standards[32] - Total liabilities rose to CNY 72.20 million from CNY 41.56 million, an increase of 74%[35] - Owner's equity increased significantly to CNY 775.49 million from CNY 315.94 million, a growth of 146%[36]